Interestingly, dupilumab reduces concentration of eotaxin-3 in nasal secretions and eotaxin-1 concentration in polyp tissues of patients with chronic rhinosinusitis with nasal polyposis. Here, CCL11 is linked to chronic rhinosinusitis.